March 9, 2023

Our CEO met with the Dutch Queen during her official visit to Slovakia

Our CEO, Dr. Pavol Cekan, had the honor of being among the most innovative representatives from the health sector who met with Her Majesty Queen Máxima on her official visit to Slovakia.

Besides other topics, they discussed potential cooperation with The Alexander Monro Breast Cancer Clinic, the first specialized breast cancer clinic in the Netherlands. The country has one of the most advanced economies in the world and ranks fourth on the European Innovation Scoreboard (2022). Dutch strengths in public-private collaborations, global talent, a skilled workforce – including tech specialists, and an overall population with above-average digital skills.

We are pleased to see our company achievements to be recognized, but there is a lot of work ahead of us!

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News